BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 13.3//EN
BEGIN:VTIMEZONE
TZID:W. Europe Standard Time
BEGIN:STANDARD
DTSTART:20231002T030000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=3;BYMINUTE=0;BYMONTH=10
TZNAME:W. Europe Standard Time
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20230301T020000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:W. Europe Daylight Time
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Time: 13:00 - 14:30 UK time\n\nAn interesting webinar with thre
e speakers looking at how pharmaceutical statisticians can engage with the
ir commercial and other business teams. Camilo Zapata will introduce the f
ield of &ldquo\;business analytics&rdquo\; in the context of pharmaceutica
ls\, Helena Baptista will talk about how we can measure the effectiveness
of our communications and Lucy Frith will speak about communicating effica
cy data in a manner appropriate for health care professionals.\n\nAbstract
s\n\n\n\n \n \n  \;\n Camilo Zapata (A
lkermes)\n Abstract: Business analytics is the &ldquo\;discipli
ne&rdquo\; in charge of identifying and leveraging meaningful patterns in
data to drive or inform business decisions. It is multidisciplinary in nat
ure as it operates at the intersection between mathematics/statistics\, co
mputer science and management. \; In this talk we will discuss how the
se three areas converge to deliver impactful results and share some releva
nt examples. We will also talk about what characteristics an organization
requires in order to leverage this discipline as in the business world the
ability to impact decisions is not only determined by the quality of the
analyses\, but also the robustness of the processes\, the skills of the de
cision makers and the approachability of the results. \;\n
\n Bio: Camilo is a data scientist that currently leads the adv
ance analytics organization at Alkermes. He focuses on everything that is
not clinical\, with special emphasis on the commercial side of the busines
s. \; Before Alkermes he led the compliance analytics efforts at Pfize
r and the Text mining and Natural language processing hub at Lilly. \;
He also co-led the creation of the advanced business analytics group at L
illy and he was responsible for building the analytical capabilities of Li
lly&rsquo\;s clinical trial supply chain organization.\n Camilo
is an engineer by training with M.S. degrees in Chemical and industrial e
ngineering and a PhD in Chemical engineering from Purdue University. In sp
ite of these titles is fair to say that as an engineer he wouldn&rsquo\;t
survive. \n \n \n \n \n Hel
ena Baptista (Lilly)\n Abstract: \;We have been measuring t
he efficacy and safety of our medicines for a long time. What are we doing
to measure the efficacy of our promotional strategies? Developing great m
edicines is key\, but if we fail to let the scientific community know when
and why they should use our products\, patients that would benefit the mo
st will hardly get access to them. We need to provide directions to the ma
rketing teams on how\, when and how often to reach the interested health c
are providers. On top\, in Europe\, we need to do that with limited access
to data. We will discuss what we can do and where do we have the biggest
challenges.\n \n Bio: \;\n \n
Education: PhD in statistics. NOVA University of Lisbon &ndash\; P
ortugal\n Professional experience: Finance\, Market Researc
h\, Operations management\, Forecasting\, Advanced Commercial Analytics (a
ctual)\n Teaching undergraduates and Mastery courses on For
ecasting Methods and Statistics for Enterprise Data Analysis\n
\n \n \n \n  \;\n Lucy
Frith (GSK) \;\n Abstract: \;Working with a commercial
organisation provides a varied array of tasks that often need complex anal
yses explained in a very concise but transparent way. This can lead to re-
use of study data to present the results in a manner that meets the specif
ic needs of different external groups such as health care professional (HC
Ps). Two such examples will be presented here. Firstly\, overlaying the co
sts of treatments and patient care onto patient outcomes to support discus
sions with payer groups. Secondly\, using Markov Chain modelling to utilis
e long-term data and provide Health care professionals a presentation of t
he data that aligns to the probability of a patient changing health status
in a given period of time. To give further context to how these presentat
ions of data could be used\, such work is reviewed using data collected in
a traditional efficacy study and in a pragmatic effectiveness situation.\
n \n Bio: Lucy is currently working in the late phas
e respiratory research and supports a range of marketed products. She has
a keen interest in re-using data appropriately to maximise the value of in
formation collected during the development of a medicine. This is to furth
er understand the products\, the disease areas of interest and presenting
this information in a practical way to external groups such as health care
professional (HCPs). \; \;\n Lucy is a statistician wi
th 26 years&rsquo\; experience in the industry\; where she has been involv
ed in the clinical program design\, taking products all the way through to
submission and regulatory approval. She has a M.S. degrees in Medical Sta
tistics and a MBA.\n \n \n \n\n\n \;\nPlease clic
k here \;to view the flyer.\n\n\nRegistration:\n\n \n \n
 \;Registration\n \n \n  \;PSI Me
mber\n  \;Free\n \n \n  \;Non-
member\n  \;£\;20 (plus VAT) \;\n \n \n\
n\nRegistration is now closed.
DTEND:20190312T133000Z
DTSTAMP:20240328T114934Z
DTSTART:20190312T120000Z
LOCATION:
SEQUENCE:0
SUMMARY:PSI Webinar: Statistical Engagement with Commercial Activities
UID:RFCALITEM638472233741565551
X-ALT-DESC;FMTTYPE=text/html:Time: 13:00 - 14:30 UK time\n
\nAn interesting webinar with three speakers looking at how ph
armaceutical statisticians can engage with their commercial and other busi
ness teams. Camilo Zapata will introduce the field of &ldquo\;business ana
lytics&rdquo\; in the context of pharmaceuticals\, Helena Baptista will ta
lk about how we can measure the effectiveness of our communications and Lu
cy Frith will speak about communicating efficacy data in a manner appropri
ate for health care professionals.
\n
\nAbstracts
\
n
\n\n
 \; \n Camilo Zapata (Alker mes) | \n Abstract:
Business analytics is the &ldquo\;discipline&rdquo\; in charge o
f identifying and leveraging meaningful patterns in data to drive or infor
m business decisions. It is multidisciplinary in nature as it operates at
the intersection between mathematics/statistics\, computer science and man
agement. \; In this talk we will discuss how these three areas converg
e to deliver impactful results and share some relevant examples. We will a
lso talk about what characteristics an organization requires in order to l
everage this discipline as in the business world the ability to impact dec
isions is not only determined by the quality of the analyses\, but also th
e robustness of the processes\, the skills of the decision makers and the
approachability of the results. \; \n \n Bio: Camilo is a data scientist that currently leads the advance analytics organization at Alkermes. He focuses on everything t hat is not clinical\, with special emphasis on the commercial side of the business. \; Before Alkermes he led the compliance analytics efforts a t Pfizer and the Text mining and Natural language processing hub at Lilly.  \; He also co-led the creation of the advanced business analytics gro up at Lilly and he was responsible for building the analytical capabilitie s of Lilly&rsquo\;s clinical trial supply chain organization.\n Camilo is an engineer by training with M.S. degrees in Chemical and in dustrial engineering and a PhD in Chemical engineering from Purdue Univers ity. In spite of these titles is fair to say that as an engineer he wouldn &rsquo\;t survive. \n | \n \n
\n Helena Baptista (Lilly) | \n
Abstract: \;We have been measuring th
e efficacy and safety of our medicines for a long time. What are we doing
to measure the efficacy of our promotional strategies? Developing great me
dicines is key\, but if we fail to let the scientific community know when
and why they should use our products\, patients that would benefit the mos
t will hardly get access to them. We need to provide directions to the mar
keting teams on how\, when and how often to reach the interested health ca
re providers. On top\, in Europe\, we need to do that with limited access
to data. We will discuss what we can do and where do we have the biggest c
hallenges. \n \n Bio: \;\n
| \n
 \; \n Lucy F rith (GSK) \; | \n Abstract: \;Working with a commercial organisation provides a varied array of
tasks that often need complex analyses explained in a very concise but tra
nsparent way. This can lead to re-use of study data to present the results
in a manner that meets the specific needs of different external groups su
ch as health care professional (HCPs). Two such examples will be presented
here. Firstly\, overlaying the costs of treatments and patient care onto
patient outcomes to support discussions with payer groups. Secondly\, usin
g Markov Chain modelling to utilise long-term data and provide Health care
professionals a presentation of the data that aligns to the probability o
f a patient changing health status in a given period of time. To give furt
her context to how these presentations of data could be used\, such work i
s reviewed using data collected in a traditional efficacy study and in a p
ragmatic effectiveness situation. \n \n Bio: Lucy is currently working in the late phase respirato ry research and supports a range of marketed products. She has a keen inte rest in re-using data appropriately to maximise the value of information c ollected during the development of a medicine. This is to further understa nd the products\, the disease areas of interest and presenting this inform ation in a practical way to external groups such as health care profession al (HCPs). \; \;\n Lucy is a statistician with 26 ye ars&rsquo\; experience in the industry\; where she has been involved in th e clinical program design\, taking products all the way through to submiss ion and regulatory approval. She has a M.S. degrees in Medical Statistics and a MBA. \n | \n
 \;
\n\nRegistration is now closed.
END:VEVENT END:VCALENDAR